When was Spero Therapeutics founded?

Spero Therapeutics was founded in 2013.

Where is Spero Therapeutics located?

Spero Therapeutics is headquartered in Cambridge, United States.

Where does Spero Therapeutics rank among its competitors?

Spero Therapeutics ranks 465th amongst 437 active competitors, of which 136 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Spero Therapeutics?

Spero Therapeutics' top competitors include BeiGene, Biogen and argenx. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Spero Therapeutics - 2026 Company Profile & Competitors

Company Details

Developer of monoclonal antibody therapies for immune mediated disease conditions. These therapeutic candidates target signaling pathways to address inflammation and tissue fibrosis. Research focuses on clinical development programs that target immune system mechanisms.

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Unfunded

Ranked

465^th among 509 competitors

Similar Companies

BeiGene & 507 more

View Spero Therapeutics' full profile

Spero Therapeutics has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spero Therapeutics include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Spero Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
4th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
7th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	68/100
9th	Theravance Biopharma 2001, Francisco (United States), Public	Developer of therapeutics for inflammatory and immunological diseases	-	Sierra Ventures, Acorn Bioventures & 6 others	68/100
10th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	68/100
465th	Spero Therapeutics 2013, Cambridge (United States), Unfunded	Developer of monoclonal antibody therapies for immune mediated disease conditions	-	-	16/100